Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPark, Keunchil
dc.contributor.authorJӓnne, Pasi A.
dc.contributor.authorKim, Dong-Wan
dc.contributor.authorHan, Ji-Youn
dc.contributor.authorWu, Ming-Fang
dc.contributor.authorLee, Jong-Seok
dc.contributor.authorFelip Font, Enriqueta
dc.date.accessioned2021-06-21T12:00:52Z
dc.date.available2021-06-21T12:00:52Z
dc.date.copyright2020
dc.date.issued2021-05-01
dc.identifier.citationPark K, Jӓnne PA, Kim D, Han J, Wu M, Lee J, et al. Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer. 2021 May 1;127(9):1407-1416.
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/11351/6087
dc.descriptionReceptor del factor de creixement epidèrmic; Càncer de pulmó de cèl·lules no petites; Inhibidor de la tirosina quinasa
dc.description.sponsorshipHanmi Pharmaceutical Co. Ltd.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesCancer;127(9)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectMedicaments antineoplàstics
dc.subjectPrognosi
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshAntineoplastic Agents
dc.subject.meshProgression-Free Survival
dc.titleOlmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/cncr.33385
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decsantineoplásicos
dc.subject.decssupervivencia libre de progresión
dc.relation.publishversionhttps://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33385
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Park K] Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. [Jӓnne PA] Lowe Center for Thoracic Oncology, The Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. [Kim DW] Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. [Han JY] National Cancer Center, Goyang, Republic of Korea. [Wu MF] Chung Shan Medical University Hospital, Taichung, Taiwan. [Lee JS] Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. [Felip E] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid33434335
dc.identifier.wos000606964500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple